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INTRODUCTION
The day is drawing near when each patient can be made into a SuperModel—not a fashion model,
but a digital or virtual model (see companion paper Brown, in review). Such representation of a
patient can also be termed a patient avatar (The Discipulus Project, 2013). Principles to help guide
successful implementation of these SuperModels are addressed in this article, including efficiency
and cost-effectiveness (Figure 1).
PATIENT-CLINICIAN-TECHNICIAN ALLIANCE
Apatient-clinician-technician alliance will be needed for optimal care. The patient will interact with
the clinician and technician, while the technician guides input of information into the SuperModel.
Upon availability of model results, the technician will help interpret output for the clinician and the
patient (The Discipulus Project, 2013). Multiple levels of support among the patient’s health care
team will be needed for shared clinical decision-making, buttressed by patient engagement and
involvement of kinship and social networks. Thus, the health care team, patient, and kinship and
social networks should be educated about the probabilistic (as opposed to deterministic) nature of
SuperModel output. This would be facilitated by systems medicine counseling (Brown, in review).
Various clinical decision support (CDS) tools are being developed for research and clinical use (e.g.,
http://www.myhealthavatar.eu, http://www.myresults.org), which help physicians decipher results
and communicate with patients and their networks.
CENTRALIZATION AND AUTOMATION
Natural-language processing and cognitive computing have been harnessed to create CDS tools,
combining guidelines, recommendations, and primary scientific literature with a virtual advisor
trained by medical experts to guide individualized care. One example is the preliminary MD
Anderson Oncology Expert Advisor, in collaboration with the International Business Machines
(IBM) Corporation’s Watson (Savage, 2014). SuperModels should be similarly vetted. To facilitate
this, centralized repositories of systems medicine pathways should be widely available to
international health care, investigative, and regulatory teams for inclusion in the SuperModels.
Models should span various databases such as the Virtual Cell (http://www.vcell.org) and run on
worldwide accessible supercomputers such as IBM cores (http://www.ibm.com) or OpenScience
grid (http://www.opensciencegrid.org). Semantic interoperability (The Discipulus Project, 2013)
should be optimized among various programming, pathway, and ontological languages, e.g.,
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FIGURE 1 | Emerging principles for precision and systems medicine. A patient-clinician-technician alliance will be needed to work effectively with patient
avatars in precision and systems medicine. The technician will feed data from the clinician and the patient into the SuperModel (in conjunction with systems medicine
counseling; Brown, in review), with input that is DISCrete: employing or amenable to diagnostics, providing relevant information, appealing to simplicity using small
prototypes specific to a particular condition within the comprehensive SuperModel. Centralized repositories will facilitate model automation. The resulting output will
be discRETE: readable, with elucidation of individualized prognosis, recommending therapeutics, and allowing for expandable iteration when new material becomes
available. The pentad principles 5LEAD should be used to guide use of SuperModels. Physiological replicas should be prepared at five levels: molecule, cell, tissue,
organ, and organism, even if all five levels will not always be simultaneously called out in a DISCRETE. Implementation of SuperModels should be economical, efficient,
effective, efficacious, and expedient (5E). Accurate annotation, abundance of replication, and allocation of systems medicine resources, particularly to communities in
most need, should ensure anonymization and safe secure accessibility to EHR-integrated data. Patient data is mapped in 5D, regarding length, width, depth, time,
and pathology (disease remission and relapse). Finally, the clinical utility, accuracy, tangible benefit, and cost-effectiveness of SuperModel or other precision or
systems medicine output recommendations should be demonstrated in reproducible assays, before existing clinical strategy is replaced or complemented; suggested
therapy and outcome prediction should be provided by the systems medicine simulations, with appropriate turnaround time (COTTAGE ART).
Molecular Interaction Map (MIM) (Tortolina et al., 2015) and
SBML (The SBML Team, 2012), in order to combine platforms.
With such standardization and homologation, systems medicine
technicians will be able to select a subset of relevant model
frameworks from a suite of SuperModel prototypes in an
automated fashion. Within these frameworks, specific categories
will be selected, including area of medicine, nation, and area of
the country, with routing to an appropriate regional supergrid.
The selection should yield the right model phenotype best
suited to address the precision medicine question: What is the
right care at the right time for this particular patient? The
SuperModel interface would therefore facilitate personalization
of appropriate model prototypes. The output would provide
customized analyses and recommendations available to the
technician and clinician. This information would also be
distilled and made available to patients in electronic portals,
via desktop or laptop computers, smart phones, and other
means of accessing the internet and mobile health (mHealth)
applications.
DISCRETE
SuperModels data should be queriable in discrete interactive
blocks that can be called out to tailor processes to the
patient encounter economically and efficiently. Each model
package or module is here termed a SuperModule, or a
DISCRETE—short for diagnostics, information, simplicity,
condition, readable, elucidation, therapeutics, and expandable.
The mnemonic DISCRETE encapsulates several guiding
principles for precision and systems medicine. Some of these
principles elaborate on suggestions made by The Discipulus
Project to help guide incorporation of computational
models into clinical practice (The Discipulus Project,
2013).
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Input to SuperModels to access a DISCRETE should
consider diagnostics in a directed fashion. Data from diagnostic
procedures would be made available to the SuperModels through
integration of electronic health record (EHR), mobile health
(mHealth) (Lippman, 2013), telemedicine (McManus et al.,
2014), and other platforms, tools, or media. The SuperModel
package itself can then be used as a diagnostic tool by
pooling data from various sources. Information about patient
characteristics can be selected from dropdown menus for risk
factors (modifiable and non-modifiable, traditional and non-
traditional), genes, environment, lifestyle, behaviors, adherence
to treatment recommendations, preferences, socioeconomics,
location, and access. Such information would also be pulled
in from patient records. The DISCRETE ensures simplicity by
providing small modules for input and analysis by the technician.
Each module, however, would be comprehensive and specific
to a particular condition or disease such as cancer, stroke, or
heart disease, each of which often associates with multi-organ
contributors, complications, or failure.
Output from a DISCRETE (or SuperModule) should be
readable by the technician and by various computer resources,
including the patient portal. Module results should lead to
elucidation of patient-specific prognosis. Therapeutics should
also be recommended. DISCRETEs should be testable, verifiable,
and iteratively expandable as new material becomes available in
literature or from the patient record. In fact, in principiomodules
can be validated as compact DISCRETEs prior to integration into
SuperModels.
5LEAD
This section introduces a second novel mnemonic that captures
pentad principles for precision medicine, which are in part
inspired by assessing theDigital Patient roadmap (TheDiscipulus
Project, 2013).
Pioneering principles for computational avatars and other
systems medicine data in precision medicine may be succinctly
encapsulated in “5LEAD.” Systems biology tools should simulate
physiology at 5 Levels: molecule, cell, tissue, organ, and organism.
This allows for analyses that can be fit to available molecular,
genomic, histopathological, or other clinical data available at
these various spatial and geometric scales among interacting
organ systems.
For incorporation into clinical practice, implementation
should be economical, efficient, effective, efficacious, and
expedient (5E). This is needed to ensure affordability and lasting
clinical utility in real-time. Health care is an expensive entity
that has so far been reactive to patients’ disease. Now we are
moving toward proactive, predictive, and preventive care. The
Discipulus Project, for example, is funded by the European
Commission with a call to provide affordable and personalized
primary, secondary, and tertiary preventive care to decrease
health care costs (The Discipulus Project, 2013). One might
anticipate that other governments, academia, industry, and
health insurance companies will serve as partners to stratify and
optimize medical care for chronic public health burdens, such
as stroke, cancer, and heart conditions. One might expect that
collaborative cost-sharing will be eased by decreasing figures
for systems medicine data procurement, similar to human
genomic sequencing costs (currently∼$1000) down from∼$400
million 10 years ago (Collins and Varmus, 2015). Existing
parsimonious methodologies also include phenomenological and
mechanistic reduction of complex physiological models (Brown
et al., 2011, 2015; Brown and Loew, 2012, 2014), and adaptive
semi-supervised recursive tree partitioning (Wang, 2015).
Such methods minimize model parameters while maintaining
authenticity, and efficiently and effectively retrieve patient
similarity data, respectively. SuperModels could conceivably
require massive computer power for execution. However,
additional steps should be followed to avoid prohibitive
computational needs. One critical step would employ Quasar, a
new engineering paradigm that increases server efficiency from
a typical 20% to an impressive 70% (Delimitrou and Kozyrakis,
2014).
Abundance, accessibility, anonymization, annotation, and
allocation (5A) are also needed. Accurate annotation and
broad replication (abundance) of systems medicine resources
should occur across nations. Allocation to communities in
most clinical need should be enhanced to provide safe,
private (anonymization), and secure access to SuperModels. At-
risk, understudied, or underrepresented populations should be
oversampled to contribute to universal avatars. These can be used
as starting points for diverse patient consultation on the way to
personalization.
Precision and systems medicine will occur in five dimensions
(5D). Each patient’s biometrics will be closely matched
holographically regarding length, width, depth, time, and
pathology (disease remission and relapse). Long-term prediction,
particularly for chronic diseases which pose an economic health
care burden, will be key for management of customized care and
resources (The Discipulus Project, 2013).
COTTAGE ART
A third novel mnemonic calls upon important additional
principles suggested by other groups. In order to compose the
mnemonic, one may consider that in the modern theme park of
science, systems biology (the study of whole organisms through
life and natural sciences) (Likic´ et al., 2010), biomarker discovery
(Ge and Wang, 2012), and pharmacogenomics (response to
drugs based on genetics) (Wang et al., 2011) sit next to bench-
to-bedside -and-clinic translation (Ritchie, 2012). There, each
discipline together takes a ride to help decide how numeric
quantitation in the human body can help with understanding
the expression, as well as concentration and regulation of normal
protein and also mutation. There, results of model studies with
mice used as examples can be compared with corresponding
phenotypes from multinational human samples. This is spurred
on by the hope that methodology integration can help with
pathophysiology elucidation (Milward et al., 2012; Botling et al.,
2013), with the ultimate goal of human disease mitigation.
Yet, before any biotechnological advance in precision
medicine can become ubiquitous, certain principles are needed
to be efficacious (Pereira and Weinshilboum, 2009). The
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testing done for each patient must have clinical utility.
Before replacement of existing clinical strategy, the test should
demonstrate superiority. There ought to be tangible benefit
and cost-effectiveness that place the patient’s needs before the
test. Biotechnology in precision medicine testing must allow
for outcome prediction, with appropriate turnaround time
facilitation. All of these requirements can be put in place with
ease of memory, using a mnemonic: COT ACE.
Precision Medicine in clinical practice can go hand in hand
with risk stratification and biomarker discovery in a way that
augments accuracy (Kullo and Cooper, 2010). Of course, this
should involve a reproducible assay, with anticipation of available
intervention via therapy. This interaction of science with the
clinical, in part, may also be governed by the mnemonic: ART.
If we put the two mnemonics together, we generate: COTACE
ART. Given the liberty we take with mnemonics and names of
clinical trials, we could choose to remain in denial, believing that
C is equivalent to G, and change the mnemonic to: COTTAGE
ART. Many mnemonics will come and go as will clinicians and
researchers, but principles stand the test of time. For this reason
COTTAGEARTmay persist in ourminds and favorably furnish a
useful guide. Perhaps as part of the Precision Medicine Initiative
(http://www.nih.gov/precisionmedicine), COTTAGE ART can
modify how clinical medicine has been practiced and enhance the
landscape that has been established.
LOOKING AHEAD
Already computational avatars have associated with
improvement of health outcomes (The Discipulus Project,
2013). Clinical trials to validate and demonstrate efficacy of
computational avatars and SuperModels as decision aids will
continuously be needed to guide clinical implementation,
initially in pilot studies with∼200–500 patients, then with larger
cohorts such as 10,000 patients (or 1 million, as in the proposed
precision medicine initiative cohort; Collins and Varmus, 2015).
Among other capabilities, Watson uses cognitive computing to
simplify and expedite matching of patients with suitable clinical
trials simultaneously underway around the globe (Lewotsky,
2014). Public–private partnerships will likely be forged by the
Food and Drug Administration (FDA) to determine regulatory
processes to help guide clinical translation of genomic testing
(Evans et al., 2015) and other systems medicine data. The
use of these technologies in clinical practice to individualize
patient care should be guided by these principles that can be
well-remembered with the three mnemonics presented in this
paper.
Important too is optimizing patient engagement. This is
already being done by providing access to avatars through
electronic portals, and facilitating communication between
patients and their health care teams (e.g., http://www.
myhealthavatar.eu, http://www.myresults.org). Open avatar
communities should be created to allow for catalytic patient-
patient peer interactions to improve personalized self-care. This
will take “peer-to-peer healthcare” observed on social media
platforms (Fox, 2011) even further and synch this behavior
with the best information possible for the particular patient in
the form of an avatar. These initiatives can be merged through
common clinical user interfaces for use on computers of various
shapes and sizes, including smart watches and glasses (The
Discipulus Project, 2013).
In conclusion, a myriad of principles have been suggested to
help guide the use of interdisciplinary models, consortia, and
platforms in clinical practice. In the context of these principles,
emerging comprehensive multidimensional computational
avatars integrated with wearable sensors, mHealth technology,
telemedicine, and the EHR (i.e., SuperModels) may help optimize
patient care in precision and systems medicine.
AUTHOR CONTRIBUTIONS
SB conceived of, analyzed, designed, drafted, critically revised,
approved, and agreed to be accountable for this submitted work.
ACKNOWLEDGMENTS
The author is grateful to Dr. Iftikhar Kullo and Dr. Joerg
Herrmann of Mayo Clinic in Rochester, Minnesota for reading
the manuscript.
REFERENCES
Botling, J., Edlund, K., Lohr, M., Hellwig, B., Holmberg, L., Lambe,M., et al. (2013).
Biomarker discovery in non-small cell lung cancer: integrating gene expression
profiling, meta-analysis, and tissue microarray validation. Clin. Cancer Res. 19,
194–204. doi: 10.1158/1078-0432.CCR-12-1139
Brown, S. A., and Loew, L. M. (2012). Computational analysis of calcium signaling
and membrane electrophysiology in cerebellar Purkinje neurons associated
with ataxia. BMC Syst. Biol. 6:70. doi: 10.1186/1752-0509-6-70
Brown, S. A., and Loew, L. M. (2014). Integration of modeling with experimental
and clinical findings synthesizes and refines the central role of inositol 1,4,5-
trisphosphate receptor 1 in spinocerebellar ataxia. Front. Neurosci. 8:453. doi:
10.3389/fnins.2014.00453
Brown, S. A., McCullough, L. D., and Loew, L. M. (2015). Computational
neurobiology is a useful tool in translational neurology: the example of ataxia.
Front. Neurosci. 9:1. doi: 10.3389/fnins.2015.00001
Brown, S. A., Moraru, I. I., Schaff, J. C., and Loew, L. M. (2011). Virtual
NEURON: a strategy for merged biochemical and electrophysiological
modeling. J. Comput. Neurosci. 31, 385–400. doi: 10.1007/s10827-011-
0317-0
Collins, F. S., and Varmus, H. (2015). A new initiative on precision medicine. N.
Engl. J. Med. 372, 793–795. doi: 10.1056/nejmp1500523
Delimitrou, C., and Kozyrakis, C. (2014). “Quasar: resource-efficient and QoS-
aware cluster management,” in Proceedings of the 19th International Conference
on Architectural Support for Programming Languages and Operating Systems
(Salt Lake City, UT).
Evans, B. J., Burke, W., and Jarvik, G. P. (2015). The FDA and genomic tests–
getting regulation right. N. Engl. J. Med. 372, 2258–2264. doi: 10.1056/
NEJMsr1501194
Fox, S. (2011). Peer-to-Peer Healthcare. The Social Life of Health Information,
2015. Available online at: http://www.pewinternet.org/2011/05/12/peer-to-
peer-healthcare-2/
Frontiers in Genetics | www.frontiersin.org 4 January 2016 | Volume 6 | Article 365
Brown Precision and Systems Medicine Principles
Ge, Y., and Wang, T. J. (2012). Identifying novel biomarkers for cardiovascular
disease risk prediction. J. Intern. Med. 272, 430–439. doi: 10.1111/j.1365-
2796.2012.02589.x
Kullo, I. J., and Cooper, L. T. (2010). Early identification of cardiovascular
risk using genomics and proteomics. Nat. Rev. Cardiol. 7, 309–317. doi:
10.1038/nrcardio.2010.53
Lewotsky, K. (2014). IBM Watson Pairs With Power Systems to Bring New Tools
to Medical Services Providers. Available online at: http://www.ibmsystemsmag.
com/power/businessstrategy/BI-and-Analytics/healthcare-pain-points/
Likic´, V. A., McConville, M. J., Lithgow, T., and Bacic, A. (2010). Systems biology:
the next frontier for bioinformatics. Adv. Bioinformatics 2010:268925. doi:
10.1155/2010/268925
Lippman, H. (2013). How apps are changing family medicine. J. Fam. Pract. 62,
362–367. Available online at: http://www.jfponline.com/home/article/how-
apps-are-changing-family-medicine/f8b317bc104214c97c499715fc79cc91.
html
McManus, R. J., Mant, J., Haque, M. S., Bray, E. P., Bryan, S., Greenfield, S. M.,
et al. (2014). Effect of self-monitoring and medication self-titration on systolic
blood pressure in hypertensive patients at high risk of cardiovascular disease:
the TASMIN-SR randomized clinical trial. JAMA 312, 799–808. doi: 10.1001/
jama.2014.10057
Milward, E. A., Daneshi, N., and Johnstone, D. M. (2012). Emerging real-
time technologies in molecular medicine and the evolution of integrated
‘pharmacomics’ approaches to personalized medicine and drug discovery.
Pharmacol. Ther. 136, 295–304. doi: 10.1016/j.pharmthera.2012.08.008
Pereira, N. L., and Weinshilboum, R. M. (2009). Cardiovascular
pharmacogenomics and individualized drug therapy. Nat. Rev. Cardiol. 6,
632–638. doi: 10.1038/nrcardio.2009.154
Ritchie, M. D. (2012). The success of pharmacogenomics in moving genetic
association studies from bench to bedside: study design and implementation of
precision medicine in the post-GWAS era. Hum. Genet. 131, 1615–1626. doi:
10.1007/s00439-012-1221-z
Savage, S. (2014). MD Anderson and Watson Are Transforming Healthcare.
Available online at: http://www.ibmsystemsmag.com/power/issues/August-
2014/
The Discipulus Project, V. (2013). Discipulus: Roadmap for the digital patient.
Available online at: http://www.vph-institute.org/upload/discipulus-digital-
patient-research-roadmap_5270f44c03856.pdf
The SBML Team (2012). The Systems Biology Markup Language. Available online
at: http://www.sbml.org
Tortolina, L., Duffy, D. J., Maffei, M., Castagnino, N., Carmody, A. M., Kolch, W.,
et al. (2015). Advances in dynamic modeling of colorectal cancer signaling-
network regions, a path toward targeted therapies. Oncotarget 6, 5041–5058.
doi: 10.18632/oncotarget.3238
Wang, F. (2015). Adaptive semi-supervised recursive tree partitioning: the ART
towards large scale patient indexing in personalized healthcare. J. Biomed.
Inform. 55, 41–54. doi: 10.1016/j.jbi.2015.01.009
Wang, L., McLeod, H. L., and Weinshilboum, R. M. (2011). Genomics and drug
response. N. Engl. J. Med. 364, 1144–1153. doi: 10.1056/NEJMra1010600
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Brown. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 5 January 2016 | Volume 6 | Article 365
